Leap Therapeutics, Inc.
NasdaqCM LPTX
Leap Therapeutics, Inc. Free Cash Flow for the Trailing 12 Months (TTM) ending September 30, 2024: USD -55.17 M
-
Leap Therapeutics, Inc. Free Cash Flow for the Trailing 12 Months (TTM) ending September 30, 2023 was USD -46.39 M, a 0.77% change year over year.
-
Leap Therapeutics, Inc. Free Cash Flow for the Trailing 12 Months (TTM) ending September 30, 2022 was USD -46.75 M, a -53.75% change year over year.
-
Leap Therapeutics, Inc. Free Cash Flow for the Trailing 12 Months (TTM) ending September 30, 2021 was USD -30.40 M, a -17.11% change year over year.
-
Leap Therapeutics, Inc. Free Cash Flow for the Trailing 12 Months (TTM) ending September 30, 2020 was USD -25.96 M, a 7.47% change year over year.
| Date | Free Cash Flow | Operating Cash Flow | Net Cash Used For Investing Activities | Net Cash Used Provided By Financing Activities |
|---|
| CEO | Mr. Douglas E. Onsi J.D. |
| IPO Date | Jan. 25, 2017 |
| Location | United States |
| Headquarters | 47 Thorndike Street |
| Employees | 54 |
| Sector | Health Care |
| Industries | |
Leap Therapeutics, Inc., a biopharmaceutical company, acquires and develops therapies for the treatment of cancer. Its lead clinical stage programs include DKN-01, a monoclonal antibody that inhibits Dickkopf-related protein 1, which is in multiple ongoing clinical trials for treating esophagogastric, hepatobiliary, gynecologic, and prostate cancers. Leap Therapeutics, Inc. has an option and license agreement with BeiGene, Ltd. to develop and commercialize DKN-01 in Asia (excluding Japan), Australia, and New Zealand. The company was formerly known as HealthCare Pharmaceuticals, Inc. and changed its name to Leap Therapeutics, Inc. in November 2015. Leap Therapeutics, Inc. was incorporated in 2011 and is based in Cambridge, Massachusetts.
Past 5 years
USD 1.86
USD 1.51
USD 3.06
USD 4.57
USD 1.56
USD 11.16
USD 1.39
StockViz Staff
January 15, 2025
Any question? Send us an email